Get the Stockscreener App
14.46
3.88%
0.54
Immunovant Inc stock is traded at $14.46, with a volume of 1.09M.
It is up +3.88% in the last 24 hours and down -2.56% over the past month.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
See More
Previous Close:
$13.92
Open:
$13.99
24h Volume:
1.09M
Relative Volume:
0.66
Market Cap:
$2.46B
Revenue:
-
Net Income/Loss:
$-323.01M
P/E Ratio:
-6.5135
EPS:
-2.22
Net Cash Flow:
$-272.30M
1W Performance:
+3.14%
1M Performance:
-2.56%
6M Performance:
-45.70%
1Y Performance:
-54.07%
1-Day Range:
$13.71
$14.52
1-Week Range:
$13.52
$15.17
52-Week Range:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
14.46 | 2.38B | 0 | -323.01M | -272.30M | -2.22 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust Corp - Defense World
Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
The Manufacturers Life Insurance Company Has $889,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Dimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey
Raymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Investor’s Delight: Immunovant Inc (IMVT) Closes Weak at 15.22, Down -3.67 - DWinneX
Ins & Outs: Biopharma players shuffle c-suite ranks - BioProcess International
(IMVT) Investment Analysis - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Wells Fargo & Company MN - Defense World
A company insider recently sold 1,925 shares of Immunovant Inc [IMVT]. Should You Sale? - knoxdaily.com
IMVT’s Stock Market Adventure: -34.80% YTD Growth Amidst Volatility - investchronicle.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Perhaps timely catching Immunovant Inc (IMVT) would be a good idea - Sete News
Immunovant registers shares for selling stockholders - MSN
Potential Price Increase for Immunovant Inc (IMVT) After Recent Insider Activity - knoxdaily.com
Market Watch Highlights: Immunovant Inc (IMVT) Ends on an Downturn Note at 14.72 - DWinneX
Stock Market Recap: Immunovant Inc (IMVT) Concludes at 14.58, a -7.60 Surge/Decline - DWinneX
Renaissance Technologies LLC Sells 108,100 Shares of Immunovant, Inc. (NASDAQ:IMVT) - The AM Reporter
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Average PT from Analysts - Defense World
Immunovant’s (IMVT) “Neutral” Rating Reiterated at UBS Group - Defense World
Immunovant Inc [IMVT] Records 50-Day SMA of $18.03 - knoxdaily.com
All change at Immunovant as Pete Salzmann retires - The Pharma Letter
UBS Downgrades Immunovant to Neutral, Price Target is $17 - marketscreener.com
Upward Trajectory: Immunovant Inc (IMVT) Posts a Slidee, Closing at 14.46 - DWinneX
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated - Asianet Newsable
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Immunovant Names New CEO, CFO - marketscreener.com
Roivant Sciences Announces Leadership Changes at Immunovant - TipRanks
Immunovant Announces New CEO Amid Strategic Shift - TipRanks
Immunovant (IMVT) Appoints New CEO Amid Strategic Changes - GuruFocus
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - TradingView
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - The Manila Times
Immunovant (IMVT) Announces Leadership Changes - StreetInsider
Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan
Alliancebernstein L.P. Grows Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
(IMVT) On The My Stocks Page - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
Wellington Management Group LLP Lowers Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CEO Peter Salzmann sells shares worth $364,941 By Investing.com - Investing.com South Africa
Raymond James Financial Inc. Takes Position in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant CEO Peter Salzmann sells shares worth $364,941 - Investing.com
Immunovant CEO Peter Salzmann Sells Shares to Cover Tax Obligations - TradingView
JPMorgan Chase & Co. Has $28.57 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant stock hits 52-week low at $13.58 amid market challenges - Investing.com Australia
Immunovant stock hits 52-week low at $13.58 amid market challenges By Investing.com - Investing.com South Africa
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Apr 23 '25 |
Sale |
14.79 |
2,349 |
34,742 |
225,370 |
| Barnett Eva Renee | Chief Financial Officer |
Apr 16 '25 |
Sale |
14.89 |
2,993 |
44,566 |
396,774 |
| Salzmann Peter | Chief Executive Officer |
Apr 16 '25 |
Sale |
14.89 |
8,321 |
123,900 |
1,178,191 |
| Salzmann Peter | Chief Executive Officer |
Apr 09 '25 |
Sale |
12.99 |
28,094 |
364,941 |
1,186,512 |
| Fromkin Andrew J. | Director |
Mar 07 '25 |
Sale |
19.60 |
8,000 |
156,769 |
91,913 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):